Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2Inhibitor, on Arterial Inflammation as Assessed With18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

[...]there are reasons to anticipate that a PET analysis that is limited to locations with evident structural atherosclerotic disease (i.e., a plaque-based analysis) might provide enhanced opportunities to evaluate a treatment effect. [...]neither the vessel-based nor plaque-based analyses demonstra...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American College of Cardiology Vol. 63; no. 1; p. 86
Main Authors:	Tawakol, Ahmed, Singh, Parmanand, Rudd, James HF, Soffer, Joseph, Cai, Gengqian, Vucic, Esad, Brannan, Sarah P, Tarka, Elizabeth A, Shaddinger, Bonnie C, Sarov-Blat, Lea, Matthews, Paul, Subramanian, Sharath, Farkouh, Michael, Fayad, Zahi A
Format:	Journal Article
Language:	English
Published:	New York Elsevier Limited 07-01-2014
Subjects:	Atherosclerosis Cardiology Confidence intervals Drug therapy NMR Nuclear magnetic resonance Statistical methods Veins & arteries
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	[...]there are reasons to anticipate that a PET analysis that is limited to locations with evident structural atherosclerotic disease (i.e., a plaque-based analysis) might provide enhanced opportunities to evaluate a treatment effect. [...]neither the vessel-based nor plaque-based analyses demonstrated a significant effect of short-term rilapladib compared with that of placebo in individuals with stable atherosclerotic disease concurrently on statin therapy.
ISSN:	0735-1097 1558-3597
DOI:	10.1016/j.jacc.2013.07.050